Literature DB >> 25908403

Cardiac depression induced by cocaine or cocaethylene is alleviated by lipid emulsion more effectively than by sulfobutylether-β-cyclodextrin.

Michael R Fettiplace1,2,3, Adrian Pichurko1,2, Richard Ripper1,2, Bocheng Lin1,2, Katarzyna Kowal1,2, Kinga Lis1,2, David Schwartz1, Douglas L Feinstein1,2, Israel Rubinstein2,4, Guy Weinberg1,2.   

Abstract

OBJECTIVES: Cocaine intoxication leads to over 500,000 emergency department visits annually in the United States and ethanol cointoxication occurs in 34% of those cases. Cardiotoxicity is an ominous complication of cocaine and cocaethylene overdose for which no specific antidote exists. Because infusion of lipid emulsion (Intralipid) can treat lipophilic local anesthetic toxicity and cocaine is an amphipathic local anesthetic, the authors tested whether lipid emulsion could attenuate cocaine cardiotoxicity in vivo. The effects of lipid emulsion were compared with the metabolically inert sulfobutylether-β-cyclodextrin (SBE-β-CD; Captisol) in an isolated heart model of cocaine and cocaethylene toxicity to determine if capture alone could exert similar benefit as lipid emulsion, which exhibits multimodal effects. The authors then tested if cocaine and cocaethylene, like bupivacaine, inhibit lipid-based metabolism in isolated cardiac mitochondria.
METHODS: For whole animal experiments, Sprague-Dawley rats were anesthetized, instrumented, and pretreated with lipid emulsion followed by a continuous infusion of cocaine to assess time of onset of cocaine toxicity. For ex vivo experiments, rat hearts were placed onto a nonrecirculating Langendorff system perfused with Krebs-Henseleit solution. Heart rate, left ventricle maximum developed pressure (LVdevP), left ventricle diastolic pressure, maximum rate of contraction (+dP/dtmax), maximum rate of relaxation (-dP/dtmax), rate-pressure product (RPP = heart rate × LVdevP), and line pressure were monitored continuously during the experiment. A dose response to cocaine (10, 30, 50, and 100 μmol/L) and cocaethylene (10, 30, and 50 μmol/L) was generated in the absence or presence of either 0.25% lipid emulsion or SBE-β-CD. Substrate-specific rates of oxygen consumption were measured in interfibrillar cardiac mitochondria in the presence of cocaine, cocaethylene, ecgonine, and benzoylecgonine.
RESULTS: Treatment with lipid emulsion delayed onset of hypotension (140 seconds vs. 279 seconds; p = 0.008) and asystole (369 seconds vs. 607 seconds; p = 0.02) in whole animals. Cocaine and cocaethylene induced dose-dependent decreases in RPP, +dP/dtmax, and -dP/dtmaxabs (p < 0.0001) in Langendorff hearts; line pressure was increased by cocaine and cocaethylene infusion, but not altered by treatment. Lipid emulsion attenuated cocaine- and cocaethylene-induced cardiac depression. SBE-β-CD alone evoked a mild cardiodepressant effect (p < 0.0001) but attenuated further cocaine- and cocaethylene-induced decrements in cardiac contractility at high concentrations of drug (100 μmol/L; p < 0.001). Finally, both cocaine and cocaethylene, but not ecgonine and benzoylecgonine, inhibited lipid-dependent mitochondrial respiration by blocking carnitine exchange (p < 0.05).
CONCLUSIONS: A commercially available lipid emulsion was able to delay progression of cocaine cardiac toxicity in vivo. Further, it improved acute cocaine- and cocaethylene-induced cardiac toxicity in rat isolated heart while SBE-β-CD was effective only at the highest cocaine concentration. Further, both cocaine and cocaethylene inhibited lipid-dependent mitochondrial respiration. Collectively, this suggests that scavenging-independent effects of lipid emulsion may contribute to reversal of acute cocaine and cocaethylene cardiotoxicity, and the beneficial effects may involve mitochondrial lipid processing.
© 2015 by the Society for Academic Emergency Medicine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25908403      PMCID: PMC4609207          DOI: 10.1111/acem.12657

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  58 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

2.  The distinct effects of lipid emulsions used for "lipid resuscitation" on gating and bupivacaine-induced inhibition of the cardiac sodium channel Nav1.5.

Authors:  Felix Nadrowitz; Carsten Stoetzer; Nilufar Foadi; Jörg Ahrens; Florian Wegner; Angelika Lampert; Wolfgang Koppert; Jeanne de la Roche; Andreas Leffler
Journal:  Anesth Analg       Date:  2013-11       Impact factor: 5.108

3.  Validity of the lipid sink as a mechanism for the reversal of local anesthetic systemic toxicity: a physiologically based pharmacokinetic model study.

Authors:  Ilin Kuo; Belinda S Akpa
Journal:  Anesthesiology       Date:  2013-06       Impact factor: 7.892

Review 4.  New pharmaceutical applications for macromolecular binders.

Authors:  Nicolas Bertrand; Marc A Gauthier; Céline Bouvet; Pierre Moreau; Anne Petitjean; Jean-Christophe Leroux; Jeanne Leblond
Journal:  J Control Release       Date:  2011-05-05       Impact factor: 9.776

5.  Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats.

Authors:  G L Weinberg; T VadeBoncouer; G A Ramaraju; M F Garcia-Amaro; M J Cwik
Journal:  Anesthesiology       Date:  1998-04       Impact factor: 7.892

6.  Evaluation of hydroxypropyl-beta-cyclodextrin in the treatment of aldicarb poisoning in rats.

Authors:  R S Verster; C J Botha
Journal:  J S Afr Vet Assoc       Date:  2004-12       Impact factor: 1.474

7.  In vitro study on mechanisms of bupivacaine-induced depression of myocardial contractility.

Authors:  J J Eledjam; J E de La Coussaye; J Brugada; B Bassoul; J P Gagnol; J R Fabregat; C Massé; A Sassine
Journal:  Anesth Analg       Date:  1989-12       Impact factor: 5.108

8.  The binding of cocaine to cyclodextrins.

Authors:  N Nesna; J Lou; R Breslow
Journal:  Bioorg Med Chem Lett       Date:  2000-09-04       Impact factor: 2.823

9.  Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity.

Authors:  Guy Weinberg; Richard Ripper; Douglas L Feinstein; William Hoffman
Journal:  Reg Anesth Pain Med       Date:  2003 May-Jun       Impact factor: 6.288

10.  Cocaine detoxification by combinatorially substituted beta-cyclodextrin libraries.

Authors:  Jiaxin Yu; Yongzhong Zhao; Mark Holterman; Duane L Venton
Journal:  Bioorg Med Chem       Date:  2002-10       Impact factor: 3.641

View more
  5 in total

1.  Intravenous lipid emulsion to treat suspected cocaine toxicosis in a dog.

Authors:  Kirsty Royle; Carsten Bandt
Journal:  Can Vet J       Date:  2020-01       Impact factor: 1.008

2.  Prevalence of cocaine and derivatives in blood and urine samples of trauma patients and correlation with injury severity: a prospective observational study.

Authors:  K D Oliveira; G P Fraga; E C E Baracat; A M Morcillo; R Lanaro; J L Costa; E M Capitani; F Bucaretchi; A I Ferreira Filho; V C Gimenes; R C S de Azevedo
Journal:  Eur J Trauma Emerg Surg       Date:  2017-11-07       Impact factor: 3.693

3.  Insulin Signaling in Bupivacaine-induced Cardiac Toxicity: Sensitization during Recovery and Potentiation by Lipid Emulsion.

Authors:  Michael R Fettiplace; Katarzyna Kowal; Richard Ripper; Alexandria Young; Kinga Lis; Israel Rubinstein; Marcelo Bonini; Richard Minshall; Guy Weinberg
Journal:  Anesthesiology       Date:  2016-02       Impact factor: 7.892

4.  Successful intralipid-emulsion treatment of local anesthetic systemic toxicity following ultrasound-guided brachial plexus block: case report.

Authors:  Nguyen Trung Kien; Nguyen Truong Giang; Bui Van Manh; Nguyen Manh Cuong; Ngo Van Dinh; Dinh Cong Pho; Vu The Anh; Dao Thi Khanh; Luu Quang Thuy; Pham Van Dong
Journal:  Int Med Case Rep J       Date:  2019-06-28

5.  Effect of Intravenous Lipid Emulsion on Clozapine Acute Toxicity in Rats.

Authors:  Bahareh Sadat Yousefsani; Seyed Ahmad Mohajeri; Mohammad Moshiri; Amir Hossein Jafarian; Hossein Hosseinzadeh
Journal:  J Pharmacopuncture       Date:  2019-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.